Image source: The Motley Fool.
Wednesday, Nov. 18, 2026
Need a quote from a Motley Fool analyst? Email pr@fool.com
Prenetics (NASDAQ:PRE) reported a sequential revenue increase driven by its IM8 wellness brand while revising its second-half profitability targets to prioritize aggressive customer acquisition. Management reported that total revenue reached $64.1 million, exceeding previously provided guidance ranges. The company stated it is utilizing a $1 billion growth financing facility from General Catalyst to fund 70% of its marketing expenditures, which allows for the preservation of internal capital for product development and inventory expansion. The company confirmed its intent to enter the retail market and expand into China by the end of 2027.
Speaker 0: Go ahead, Shannon.
Operator: Good morning, everyone, and welcome to Prenetics' Third Quarter 2026 Earnings live stream. I am Shannon Devine, and I will be your host today. Joining us this morning are Danny Yeung, Chief Executive Officer of Prenetics and co-founder of IM8, and Brian Rosin, Chief Financial Officer of IM8. Before we begin, please note that today's presentation contains forward-looking statements, including guidance. These statements involve risks and uncertainties, and actual results may differ materially. Please refer to the company's filings with the SEC. The full Q3 2026 shareholder letter and this investor presentation were published this morning and are available at ir.prenetics.com.
Before we hear from Danny, let us watch a short 90-second video on what Prenetics and IM8 have achieved over the past 22 months.
Danny Yeung: Prenetics is the parent company of IM8. You know, we created this supplement. Great nutrition, simple. IM8 just covers everything in one sachet. What are you willing to do to be the best? You should get IM8 because it has 92 ingredients. That's your secret, IM8? That's my secret, IM8. You know, you don't have to take 15 or 18 tablets every single morning. It's just easy, and it's so good for you and the longevity of your life. The moment that I took IM8, man, I've been feeling incredible. IM8 gives me that immunity and strength that I can wake up every morning and feel good and perform well.
I think for me, not only has my doctor recommended it to me, I know IM8's done so much scientific research, and so that makes me feel like I'm in really safe hands with IM8. It's amazing product. It's really working. That's why I choose IM8. With this $1 billion growth financing, we're able to test so much more, go into more channels, test new creatives, test new offline activations, partnerships.
Operator: The best choose the best. I will now turn the call over to Danny Yeung, Chief Executive Officer of Prenetics. Danny?
Danny Yeung: Great. Thank you, Shannon. Good morning, everyone. Thank you, everyone, for joining us. I'm Danny Yeung, co-founder and CEO of Prenetics. Joining me is also Brian Rosin, our CFO designate. Brian will succeed Steven Lo as CFO on December 31st. Since joining IM8 in May, he has helped secure our $1 billion growth financing commitment from General Catalyst, set up our finance leadership in the U.S., meeting with hundreds of investors and speaking to many new research analysts. I also want to thank Steven for his eight years at Prenetics. Steven, thank you for your dedication and partnership. I'm glad you will continue with us as a senior advisor. Let's get started, everyone. Again, thank you guys for joining.
Now to the quarter. Let's get to slide four. Let me start with the promise we made last quarter. We said adjusted free cash flow would turn positive in Q3. It did at $4.1 million, $27.5 million cash used in operations, more than offset by $31.6 million of net funding from General Catalyst. We said revenue will be between $63 million and $64 million.
Speaker 4: Anyone can start an SIP in U.S. stocks at just $1.
Speaker 5: Make money matter. Explore global investing on HDFC SKY. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Danny Yeung: We have chosen to move. We now expect a second half adjusted EBITDA loss of $30 million-$35 million against the $8 million-$12 million we previously provided. We realize this is a very large change, and it is also a deliberate choice given the returns we are seeing. Our cash growing, the General Catalyst financing, 70% of our marketing, new products on the way, and how early we are in this category. We are investing more, and I will explain why in a few minutes. As mentioned, total revenue was $64.1 million. IM8 contributed $62.9 million, up almost 40% from Q2. We did that while bringing down our cost of acquiring a customer for the second quarter in a row.
IM8 revenue has now grown for six consecutive quarters. September was our strongest month ever at $23.7 million of revenue, equivalent to an annualized revenue run rate of $284 million. Next slide. Those are the headline results. What matters more is what sits underneath them, and there is one number I will keep coming back to. Thus far, for every dollar we have invested in acquiring customers through the first six quarters of this year, those customers have now returned $1.68. That is gross profit. It is what is left after we make and ship the product. It is actually measured the same way General Catalyst measured it, and on a more conservative margin than we actually earn.
Keep in mind, when General Catalyst made that commitment back in July, that dollar was roughly $1.44, so it continues to compound on a monthly basis. And then a key metric also is that, hey, where does that number go off to, right? How does it evolve over time? Our early customers now show us this. Next slide. As you can see, this is actually taking our earliest cohorts. I think, again, this is a big part of the reason why we are investing more into the business, because as you can see here, our first full quarter of business, which was in Q1 of 2025, where we had 27,000 customers that we acquired last year.
Now with this cohort, this cohort has now returned to us $4.10 of gross profit for every dollar that it cost us to acquire them. We did this in under two years. A lot of you guys know, being in the DTC subscription base, the one key metric that is a gold standard is, hey, if we can hit it, this is going to be a solid business. That metric is having a 3:1 LTV on CAC ratio based upon gross profit. We have been able to hit that on our first cohorts.
As you can see on the next two cohorts, which is 91,000 customers that we acquired in the second and third quarters of last year, it is roughly about 2.7:1 right now. Based upon the current pace, we expect to get there in early 2027. One thing to keep in mind here, though, these early customers cost us less to acquire, roughly about $104 each against currently $285. Today's customers, they actually spend far more on first order, approximately $207 versus $113, and they are earning back what they cost us in about six months.
Our bar for these cohorts is still the same, 3:1, and typically, this 3:1 benchmark is roughly within 36 months, and we have been able to show it now for our approximately three cohorts. We are going to do this in approximately less than two years. Next slide. With those returns in mind, I am just going to answer the question I expect many of you will have for myself and Brian. We delivered a revenue guide. Why is the loss larger than the range that we gave in August? As mentioned, we now expect a second half adjusted EBITDA loss of approximately $30 million-$35 million. In August, we said $8 million-$12 million.
Right now, we are choosing to invest in growth due to the weight of the evidence we have on hand, and every quarter is more evidence of that. I will provide this to you in five different parts. The first part, as you have just seen, in more than 4x on our earliest customers, close to three on the next 91,000, and about six months to earn back what a customer costs us today. Second reason, this past quarter, we spent a record amount and brought in our largest group of new customers ever. September alone brought in more than 52,000 new customers, and four in 10 of them paid for three months upfront.
We pressed the hardest in September, which cost us more per customer than July did. Even so, our average cost for the quarter fell for the second straight time to approximately $285 in terms of customer acquisition costs. The third reason, this quarter, we grew 38%, and our cash grew too. We ended September. That is because this was the first full quarter of our $1 billion commitment from General Catalyst, and it worked as designed. They financed 70% of what we spent to acquire customers and are repaid from a capture of what those same customers bring in. That leaves our capital for new products, three clinical trials, and for a lot of brand marketing.
And four, what is coming in 2027? Every return I just showed you was earned on our core products alone, which is basically two products. IM8 Hydration arrives in the first quarter of next year, and since August, we have signed Care Bears by IM8. Every customer we bring in now is someone we can afford, that we can offer a second and third product to at no further acquisition costs. Number five, the opportunity. I mean, it is quite crazy to think, even after extraordinary growth in the past 22 months, we still only hold a 0.14% of a $200 billion category, which, quite frankly, does not have a dominant leader.
However, this is not an open-ended commitment to spend. We will keep investing at this pace for as long as we see these returns hold up. The two numbers that govern it and how we judge it by a quarterly basis is what it costs us to acquire a customer and the gross profit each group of these customers returns to us. If either of these turns against us, we will slow down, and you will hear it from us first. But you put those five together, and the expensive mistake would actually be to invest less. We are doing it from a strength.
The business we have already built earned $30.6 million this past quarter before acquisition marketing and brand partner costs. If we stopped acquiring new customers tomorrow, the customers we already have today would already make the company profitable on an adjusted EBITDA basis. Everything I have shown you so far comes from our own data. As we showed last quarter, we actually got independent credit card data from Indagari. You do not have to take our word for it. Now we can test this through an independent lens. Keep in mind, this is observed credit card activity in the U.S. only, with partial coverage of our own store rather than our reported revenue.
I will start with retention, because in the subscription business, it decides everything. We have now only been in business for 22 months, but you can see now after 22 months, 11% of IM8 customers are still buying from us. That compares with 8.7% for Thorne, 8.5% for AG1, and 7.4% for Grüns. The same panel shows how fast we are growing. Next slide. In the first nine months of 2026, the IM8 sales in the panel grew 348% year-over-year, and our share of these four brands went from 1% in January last year to 16% in December. We have the full investor deck as well as the full slides in the shareholder letter for everyone to read.
We also see the same loyalty in our business. About 59% of customer billings this quarter came from repeat orders. Quarterly plans were about 61% of September billings, and we ended September with roughly 160,000 active subscriptions. What we are saying is that if customers stay, we have one of the best retention cohorts in the category. How do we keep reaching new ones? Next slide. Our partners are the big part of the answer. As everyone knows, David Beckham co-founded IM8. The people alongside us include Giannis, Aryna Sabalenka, Ollie Bearman, Jay Shetty, Lily Collins, Inter Miami, and as of this week, Diplo. Six of these individuals joined us just this year.
Every one of them is a shareholder in Prenetics, and because we want partners who care about what the company becomes over years. The interesting thing also is that every one of these individuals reached out to us, which is a great sign that they have tried the product, they tested the product. In October last month, we went a step further. We became the Official Nutrition Partner of the NBA across Australia and eight Southeast Asian markets across 660 million people. This is also the first time ever the NBA has actually partnered with any supplement brand on a global basis. Next slide.
Before we get here, I just want to talk about, again, partners open the door, but the product has to earn its place, and this is where the science comes into play as well. We have currently already a completed randomized control trial behind our flagship. We currently also have three further randomized placebo-controlled trials underway, two in longevity and gut health, and we expect to report the results by the first half of 2027. The third trial that we have ongoing right now is an investigator-initiated study at Mayo Clinic in Florida involving 100 healthcare workers. These are studies and not results, and we will publish what we find.
Of course, this is the evidence behind what we sell today, and now let me talk about what comes next. IM8 Hydration is planned for the first quarter of 2027. We previously mentioned that we would launch Hydration Q4 of this year. We moved the timing given Q4 is such a busy time with Black Friday, Christmas sales. We wanted to have its own quarter where we can promote one product, and we will do this in Q1. What excites me is the feedback that we have been getting from all of our ambassadors about our Hydration product that have been already using it for many months. They keep coming back to it.
They keep texting me for more, so I know it is going to be an amazing product. I have also been taking the product myself in the afternoon, and it has become a routine I look forward to. Hydration is the first of two launches next year. Care Bears by IM8 is the second, targeted for the second quarter of 2027. With Care Bears, what we did is we signed a 10-year exclusive worldwide partnership with Authentic Brands Group. We are going to start with Gummy Multivitamins for children and adults. Over time, we plan to expand into better-for-you confectionary and wholesome children's snacks and foods. I am personally excited about this because it brings our work into the family.
Parents who grew up with Care Bears can introduce those characters to their own children through a daily wellness routine. We will operate the brand, recognize its revenue, and pay Authentic a royalty. And keep in mind, this royalty is not double counted by the royalties for IM8. As part of this partnership, Authentic will also become a strategic shareholder in Prenetics, a partner with deep experience building endearing brands. Angela, can you just play that short video that we launched about a few weeks ago just to give everyone an idea of the content that will be able to take place due to this partnership?
Speaker 2: Emergency Caring Council meeting to order.
Alex Nowak: First up, our new self-care initiative.
Speaker 2: This should have been an email. We are launching Care Bears Gummy Vitamins. Let's go! Woo-hoo! But we are not science experts. That is why we are teaming up with IM8. Co-founded by David Beckham? Bro, legendary! All in favor?
Alex Nowak: Yes!
Speaker 2: Let's go! Absolutely. I am in. Fine. Meeting adjourned.
Alex Nowak: Care Bears by IM8, launching in 2027.
Danny Yeung: That just gives you a glimpse in terms of what is possible. I mean, I grew up with Care Bears. I know a lot of my friends grew up with Care Bears, and this will also take us into the retail shelf, and so that is going to be quite exciting as we expand there. Next slide. As you can see, those are our new products. Let me put next year in one picture, starting with what is in our guidance. As mentioned earlier, we are reaffirming our guidance of $400 million in 2027. That is entirely built on our current two products our customers buy today. It includes nothing from our hydration category as well as from Care Bears.
About 44% of it comes from customers and channels we already have, in terms of the $156 million you see on this slide here. And we will have about $19 million more coming from marketplace and B2B. That is before we acquire a single new customer in 2027. This is a forecast and a projection, and as you can see, there are two more moves that are planned beyond the launches, and neither of that is also in the guidance. As mentioned, retail is also not in the guidance, and we are developing Care Bears with a retail-first focus along with a DTC strategy.
The second big opportunity, which is also not in this forecast, is China, a supplements market of roughly $50 billion. We intend to launch in China by the end of 2027. Both depend on finding the right partners and on the right local regulatory requirements. Now, kind of stepping back and kind of taking a look at how early we are. In under two years, we went from zero to a run rate of $284 million. That is 0.4% of a $200 billion global opportunity in a category, and this category has no dominant leader. On industry data, no company holds more than about 5% of it.
If you think about 1% of our core markets alone would be more than $1 billion a year in annual revenue, which is an illustration, not guidance. But it is also the other half of why we are investing now. So put it all together, next year for the first time, we will have three engines operating rather than one. We will have our core daily nutrition business, Hydration, and Care Bears by IM8. I have personally never been more excited about what is in front of us, but I want you to and outlook.
Brian Rosin: Thanks, Danny. Good morning, everyone. Thanks for joining us. First, I am grateful for the confidence that Danny and the board have placed in me, and for Stephen, for your great partnership through the transition. During the six months here, much of my work has gone into building a long, cost-effective financing runway for IM8’s record growth, for the quarters ahead and the years beyond. That includes helping secure the growth facility of up to $1 billion with General Catalyst and gaining an intimate understanding of our customer costs, our returns, our cash conversion cycles, margin expansion opportunities. Today, I will show you a reflection of that continuing work.
I will focus on the results, how we funded the quarter, and what is included in our outlook. Unless I say otherwise, the financial figures I discuss here should be seen as Prenetics Group’s continuing operations. Third quarter revenue was $64.1 million, up 37.9% sequentially, and approximately 3.3 times last quarter, Q3 of 2025. As seen on the screen, IM8 revenue was $62.9 million, up 39.8% sequentially, and approximately 3.7 times versus third quarter last year. Both figures came in just above the top of the ranges that we provided last quarter. IM8 now accounts for substantially all the group revenue, which also explains our moving to a single CFO structure. Those are the top lines.
Let us walk through the full P&L next. Okay, so here is the whole quarter on one page that shows the strong progression of 2026. You will note it has been a really strong story of expanding leverage on most areas of the P&L. We talked about revenue up 38% sequentially. Gross margin here of 64% in the quarter. Actually, it was a small step down. This was caused by a one-time inventory charge of $1.3 million related to older formulations. We reformulated the product, and these older formulations were written off in the quarter, which caused a slight step down. We expect the margin to continue at 65% into Q4 and beyond.
Operating costs, these are payments, people, R&D, and everything else we control. These fell from 25% of revenue in the first quarter now to 16%. So great leverage on this line. That will continue. This operating leverage is why contribution profit reached $30.6 million, or 48% contribution margin. We publish contribution profit and contribution margin because it shows the profitability of the business before a single growth dollar is spent. Since spending those dollars is a capital allocation choice we make deliberately, and against historically very strong cohort returns.
Below contribution sits the growth investment, as you can see there, $40 million of acquisition marketing, plus our royalty and ambassador cost lines that have now dropped to 5% of revenue combined in the quarter. That leads to an adjusted EBITDA loss of $12.7 million, or a negative 20% EBITDA margin, improved from negative 39% last quarter. That entire adjusted EBITDA loss is driven by the growth investments, and we gained net leverage across the P&L in almost every other area. From there, that bottom table will take you to the IFRS net loss of $25.4 million. This is relative to the $9 million in Q2.
You will see that loss includes a $7.2 million non-cash fair value loss on our warrant liabilities. This charge will rise when our share price rises, as it did in Q3. You will also notice that Q2 had benefited from a fair value gain as well as a disposal gain back in Q2. Of all those lines, of course, the one that deserves the most scrutiny is the $40 million of acquisition marketing. So let's turn to the next slide here and look at what that bought us. As Danny Yeung mentioned, we saw our second consecutive quarterly decline in CAC, which is great to see. We acquired a cohort of 137,892 new customers, up approximately 16% versus prior quarter.
The IM8 marketing spend was $39.3 million in the quarter, up approximately 10% from Q2, which leads you to a customer acquisition cost of $285, down from $301. Last quarter when we reported, we had showed July was at $239. This was an unusually strong month for the brand, was not a level we were planning around, nor do we plan around that number. The rest of the quarter, obviously if you do the math, saw $28 million of spend at a $310 CAC. September, as Danny Yeung had mentioned, was a new record cohort with 52,696 new customers. Great month. Our new customer AOV was also flat versus Q2 at $207. So consider what all this means.
Since the first quarter, we have grown ad spend from just over $18 million on IM8 brand to $40 million in Q3, and CACs have declined by 7%. At any scale, not to mention at tens of billions of dollars of quarterly increases, this usually goes the other way, where CACs will usually go up, not down, with that much more spend. This goes to show you how strong the brand is and how strong our marketing engine's performing. It also goes to show that despite the flexibility the General Catalyst facility gave us to finance growth starting this quarter, we are continuing to remain really disciplined with our capital allocation.
Next, look at the General Catalyst facility and how this works. Let's briefly remind ourselves on this framework. As we announced in July, the Customer Value Fund partnership provides a growth commitment of up to $1 billion. Of course, this is not $1 billion of capital on our balance sheet. We draw against this $1 million over time against 70% of our acquisition spend each month.
As each cohort comes in for that month that was funded, General Catalyst will receive 70% of the gross profit associated with that cohort each month as those subscriptions renew until they have recovered their principal, and then depending on how long it takes them to recover that principal, they will receive a defined premium on top of that principal. After the principal's repaid is when that premium is actually paid. What that premium is, if we look at the next slide, it depends on the speed of the payback. You can see here on the right side, the different ranges of payback speeds, and if you fall within those ranges, you can see the percentages there.
Once the principal plus the premium has been paid for a cohort, General Catalyst's participation in that particular cohort ends, at which point then all the profit from those cohorts is ours, and it had been pre-funded in a strong cash flow sort of way. This structure allows us to fund the portion of acquisition investment with the future receipts each cohort's intended to generate. Also a reminder, this financing is non-dilutive. This cost of the financing is really just this premium share that we are laying out here on the right side. That is the only cost of it.
Since their return generates, since their return rather depends on the same two numbers that we manage the business by, what a customer costs to acquire and what each cohort returns, discipline's inherently built into the way that the growth is financed, and in that way, it aligns our incentives with the facility. Turning to the next slide, since this is the first quarter that General Catalyst will show up on our financial statements, I thought it would be good to actually show here specifically in Q3 where to look for them so you can go look for yourselves. On the P&L, the entire footprint is in the financing cost section below EBITDA.
Revenue, gross margin, acquisition marketing, all those things are completely unaffected by the General Catalyst facility. All you will see is the $0.8 million of effective premium accrual in financing costs. This is below Adjusted EBITDA. On the balance sheet, you will see that the $34.7 million is there. That is the borrowings, which includes $31.6 million that we received in net cash fundings, and there is $2.3 million of true-up that was owed by General Catalyst at the end of the quarter that was settled in October, and there is $0.8 million of accrued finance costs also within that line on the balance sheet. On the cash flow statement, you will see this coming as cash from financing.
As it relates to adjusted free cash flow, which is a non-IFRS metric, this is our operating cash flow, which in the quarter is negative $27.5 million, net of CapEx, which brought to zero in the quarter, plus the GC funding of cash, which is that $31.6 million of inflow, which puts our adjusted free cash flow for the quarter at $4.1 million positive, and our ending cash balance that increased for the quarter. Let us turn to the balance sheet and look at that real quick. September ended with $111 million of cash and current financial assets, up from $109.4 million at the end of Q2.
That total comprises of $63.4 million of cash and cash equivalents and $48 million of current financial assets. Inventories increased to $20.1 million compared with $14 million at the end of Q2. We also separately increased deposits and supplier prepayments with our manufacturers to prepare for the holiday quarter and the products planned for next year. The balance sheet contains the $34.7 million of borrowings under the General Catalyst agreement, as we saw in the last slide. For the first quarter of availability, the partnership really performed exactly as we intended it to.
We were able to grow cash balance in a quarter when, one, we spent a record marketing investment to acquire our largest quarterly customer cohort we have ever had, and two, significantly bolster our inventory reserves in prep for a big Q4 and into next year, especially with some new product launches. Next, let us turn to our outlook. We are reaffirming our full year 2026 total revenue guidance of $220 million-$230 million, including IM8 revenue of $215 million-$222 million. Subtracting the nine months as reported from those figures, the fourth quarter works out to approximately $73 million-$83 million for the group and $73 million-$80 million for IM8.
We expect a second half adjusted EBITDA loss of $30 million-$35 million, compared with a negative $8 million-$12 million range that we gave back in August, as Danny mentioned. With that $12.7 million in Q3, the range implies a fourth quarter adjusted EBITDA loss of roughly $17 million-$22 million. This loss is bigger in terms of dollars, but as a percent of revenue, it actually improves from 31% in the first half to 23% in the second half at the midpoint of our guidance. Within the second half, more of it falls in the fourth quarter, about 25% of revenue as an adjusted EBITDA loss versus 20% adjusted EBITDA loss in Q3.
This is deliberate increase in customer acquisition spend that we're planning. Under two years, the next 91,000 customers are at 2.7 times, and those will pass the 3.0 mark by early 2027. CAC has also declined two straight quarters, as we mentioned, and we will look to continue investing in Q4 for the same reason, for as long as our returns will hold. We expect adjusted free cash flow to remain positive in Q4 again, despite the negative operating cash flow due to the General Catalyst financing. We're also affirming IM8's annualized revenue run rate to hit at least $300 million by year end.
Our operational investment focus for Q4 is deliver against the demand while preparing for our exciting product launches that we mentioned earlier. For 2027, we're reiterating our revenue guidance for IM8 to $400 million or more on the current product catalog. This includes no revenue from hydration, Care Bears, other products, retail, or China. All of that is outside of the current guidance. Of course, as Danny Yeung showed, that forecast, none of it is earned. We have to remain focused on retention, efficient acquisition, and execution across the year. Lastly, for the first time, we're publishing a long-term financial framework.
This is a question I get asked a lot about, what does the business, as it matures, start to look like from a margin standpoint? I thought this would be really helpful to show. Over time, we'll be targeting a gross margin of 70%-75%. We'll be targeting operating costs of 8%-12%. Brand royalty and ambassador costs should drop to 3%-5%, and our acquisition marketing should drop to 35%-50%, which would put you to an adjusted EBITDA margin of 15%-25% for the business as it matures. You can see just through the progression in 2026 that we're well on our way towards these numbers.
Still quite a bit of work to do, and none of this is guidance, and we don't have a set timeline on any of this, but this is what you should be looking for us to be moving towards on all these lines. Gross margin in particular, we've onboarded a new third-party manufacturer in Q3. They will come online in Q1. With that, we're going to be adding additional capacity and lower production costs, so our gross margin is expected to improve in the early part of 2027. We're not yet ready to say specifically what the guidance for gross margin will be yet in Q1. Look for some of that next quarter.
Our operating costs don't rise with every quarter, and that will allow us to really gain some more leverage. Royalty and ambassador costs are the same way. Acquisition marketing will, of course, fall over time as our subscriber base grows and as more revenue comes from our existing base. Again, to be clear, these are not long-term targets and not guidance for any particular period, but hold us to these metrics as this is what I'm looking to drive us towards. Moving our finance leadership to the U.S. brings us closer to our largest market and primary capital market. Cindy Tat joined us in August as our VP, Financial Controller.
She is an important part of our build-out, and you can expect us to continue adding experienced U.S. leadership in the coming quarters. Thank you to all of our Prenetics and IM8 teams for their tireless support, and thanks to all of you for joining us today. I will give it back to Danny now for closing remarks, and then we will open it up for questions.
Danny Yeung: Thank you, Brian. Before we open up for questions, let me leave you guys with a few points. Revenue is growing, cash is growing, and the community of people who trust IM8 is growing faster than ever. Very, very few companies get a window like this, least of all in a category as crowded as supplements. A brand that is getting stronger every month, a partner financing 70% of what we spend on acquiring customers, and data that shows what every cohort returns. We are building for the long term, and the path is very clear. New products, new sales channels, new marketing channels, and deeper international markets. We can be profitable tomorrow if we choose to be.
Right now, we are choosing growth. We also have a very detailed shareholder letter and investor deck of 70 pages, and I suggest everyone to look into that and review that. For now, again, thank you everyone, our customers and our shareholders, and everyone who joined us today. Again, I am happy to take questions from anyone.
Operator: Thank you, Danny and Brian. We will now open up the floor for questions. If you would like to ask a question, please use the raise hand function at the bottom of your Zoom window. I will then announce and please unmute yourself to ask your question. We will get to as many as we can and pause now while we allow for people to queue. Our first question comes from Eric Des Lauriers of Craig-Hallum. Eric, you may go ahead.
Eric Des Lauriers: Great. Thank you for taking my questions. Congrats on another strong quarter here. Both China and retail, some nice updates there. I'd just like to unpack both those opportunities. Can you just help us understand what needs to be done before you launch into both China and retail, whether that's new investments you need to make, capabilities you need to develop, or relationships you need to develop? Can you just help us understand the pathway to both entering China and then your plans for entering retail as well?
Danny Yeung: Sure. I'll start with the retail piece, because as we've heard, that's probably less complex than China. Retail-wise, the interesting thing is, with our current two product SKUs, we've actually been, I would say, every single major retailer in the US has inquired for us to get into retail. We haven't done so yet because we haven't felt like it was the right product yet. But with Care Bears and the hydration products, these two products being less expensive than our current SKUs, we feel this is much more targeted at a retail opportunity. We are speaking to all the big box retailers right now. We do expect to be in retail shelves by the end of 2027.
Of course, we haven't had any experience in retail in the past, but we haven't had experience doing DTC and we've been able to accomplish amazing things with that, right? Our capabilities, we do believe, are very transferable to the retail. We will definitely need to hire a few new people in the U.S. to be able to manage that retail big box relationship. But we're very confident that we can do so. China-wise, again, China is a much, much more complicated market. We're working with a few different potential partners to enter China with people that know the market, know the industry. Again, because in China, the way it works is no one actually transacts on your own website.
Everything is through third party, Tmall, JD, Douyin, Red Book, et cetera. Given my resources, my network there, I'm very confident that we'll be able to identify a very trustworthy partner and be live in China by the end of 2027.
Eric Des Lauriers: All right. That's great, Danny. I appreciate that. Just last one from me. Can you just talk about some of the dynamics impacting customer acquisition costs? Obviously, nice to see the sequential declines. It was down in July and then up in August and September. Just what drove some of those fluctuations, and how should we think about those dynamics going forward?
Danny Yeung: Yeah, I think the dynamics going forward, because there's always going to be fluctuations, depending on monthly, quarterly, the renewal process. That's why moving forward-wise, it's much better to understand on a quarterly basis in terms of our CAC. I think the great thing about the CAC is that you see for at least the two consecutive quarters, our CAC actually declined. If you look at Q1 to Q3, our spend more than doubled while having a reduced CAC. We feel that's a very significant figure, because typically when you're spending so much, your CAC, almost every reason, it continues to go up. We've been able to reduce that.
That gives us even more confidence to continue to invest into growth. Again, given in terms of investing growth, reality is every single new customer that we're acquiring now primes us to be even more successful when we're launching Hydration, Care Bears. We get more brand presence when retail hits. In many ways, we want to be much more aggressive now in this investment opportunity, given that we're seeing so strong returns.
Eric Des Lauriers: Just in terms of how we should think about that going forward, do you expect these sort of broad, call it roughly 300 level? Is this the right way to think about it for, just call it the next couple quarters? Obviously, some of this can fluctuate. But is this sort of the right range that you're continuing to see?
Danny Yeung: Right. I think that's the right range. I would say within 10%-15% range within that 300 mark, right? Because again, depending on seasonality. I'm sharing on Q4, everyone's going to be bidding up against acquisition, bidding auctions, and et cetera. Q1, of course, there's also going to be opportunities from a decrease when we do certain offline events. All of this put together, but I would say roughly 300 plus or minus 10%-15%.
Eric Des Lauriers: That's very helpful. Thanks again for taking my questions, and congrats on another strong quarter here.
Danny Yeung: Right. Keep in mind with the CAC-wise, one thing is that's also very interesting because if you just look at the CAC that's been increasing over the last, let's say, three to four or five quarters, a key component of that, our CAC has increased, but our average order value has increased compared to 2022, right? So our average order value is now well above $200, where again, for a new customer coming in is quite significant.
Eric Des Lauriers: Yeah, absolutely. Yeah, another great sign. Thanks for taking my questions.
Danny Yeung: Thank you, Eric.
Operator: Thank you, Eric. Our next question comes from Bill Sutherland of StoneX. Bill, you may proceed.
Bill Sutherland: Thank you. Hey, good morning, guys. I wanted just to I don't think you discussed the marketing.
Speaker 10: If you trust FDs, you're going to love what's next. Welcome to Grip Invest. Grip helps you earn up to 12.5% returns. Still fixed? Hi, I'm Nikhil, founder of Grip Invest. After 15 years with banks like HSBC, Morgan Stanley, and the World Bank, I realized one big gap in India's investment market. Most people think fixed only means FDs, but fixed returns can come from so much more. That's why at Grip Invest, you'll find bonds, SDIs, all in one place, with up to 12.5% returns. That's why more than six lakh people already trust Grip. You can start with just INR 1,000. Download the Grip Invest app and begin your fixed return journey with us today.
Speaker 11: Investments in debt securities, principal debt securities, securitized debt instruments are subject to risks, including delay and/or default in payment. Read all the offer-related documents carefully.
Bill Sutherland: Are you kind of in test mode at this point, Danny, with those other channels? Would you expect just better performance overall with a diversified mix?
Danny Yeung: I would say some of these are still in test mode, but of course, some of these have already passed beyond test mode. That is where I do believe a big reason why you have seen our CAC actually drop, basically since Q1 of 2025, is the diversification of all these channels. If we just stuck to Meta alone, our CAC would have went very, very high. Because of this diversification, we are getting much more efficient in the marketing aspect of things. We do believe when we get into retail, that will also be another channel where I think we will have even greater efficiency.
Bill Sutherland: One last one for me. The performance with the earliest cohorts, clearly very strong. Is there any reason that we shouldn't think that the latter cohorts, I am just thinking about the higher acquisition costs, et cetera, that the latter cohorts won't exceed the three to one, just like you are seeing in the early ones?
Danny Yeung: Yeah, we have every reason to believe it will follow the same pattern as our earliest cohorts. If we look at the earliest cohorts, it is already returning at 4.1, and this is actually less than two years. The next 90,000 individuals, which are the Q2 and Q3, again, they are already at 2.7, and they are going to be approaching 3x in early 2027. We have every reason to believe that it will also approach similar. Keep in mind, all these earliest cohorts only had two products. In the future, we are going to be releasing more products.
In the first half of 2027, there is going to be IM8 Hydration, there is going to be the Care Bears Gummy Vitamins for kids and adults. You should actually expect to see this continue against even our latest cohorts.
Bill Sutherland: Okay, great. Thanks for the update, guys.
Danny Yeung: Thank you, Bill.
Operator: Thank you, Bill. We will go next to Susan Anderson of Canaccord. Susan?
Susan Anderson: Hi, can you hear me?
Danny Yeung: Yes. Hi, Susan.
Susan Anderson: Hi, good morning. Nice job on the quarter. I guess I wanted to maybe just ask around the marketing around the new products that you're rolling out, particularly as they go into retail, such as the Care Bears. I guess just curious what the plans are around marketing, if it's going to be a similar marketing strategy for your current core product, or will you switch it up just given that some of it will be going into retail? Thanks.
Danny Yeung: Yeah, of course, there will be difference in terms of offline marketing-wise. We're going to be doing lots of offline activations together with the big box retailers. There are going to be a lot of end cards available at the offline retailers. We're going to be also driving a lot of online to offline traffic, which we haven't done before. I think the great thing is that, again, with Care Bears and the hydration products, these are already, I would say, at least in the wellness supplement category, two of the most sought-after products that people search in retail.
Then, again, going back to all of the brand investment that we're making now, when we are in retail, people will recognize IM8 already. Because the last thing you want, and a lot of the reasons, again, I study a lot of this stuff in terms of go-to-market strategy, is when a brand gets into retail and there's no demand. You need to be able to drive that demand because no one recognizes that brand. I think a lot of the brand equity, the brand investments that we're making today are going to pay off significantly when we get into retail channel.
Susan Anderson: Yeah. Okay, great. Then maybe just one follow-up. I was curious just kind of the-
Danny Yeung: Also, Susan Anderson, one other thing I can add that's also going to be a big plus for us, for Care Bears specifically, is that next year is Care Bears' 45th anniversary. So by default, Care Bears by themselves are going to be doing lots of offline physical activations, online as well. So that's naturally going to help us in terms of brand recognition or people understanding the brand better.
Susan Anderson: Yeah. Okay, great. Thanks so much.
Operator: Thank you, Susan. Our next question will be from Jonna Kim of TD Cowen. Jonah? Jonah, please unmute.
Jonna Kim: Can you hear me? Sorry.
Danny Yeung: Yes.
Jonna Kim: All right. Thank you for taking my question. Hi, Danny. Hi, Brian. On IM8 itself, how do you think about the distribution opportunity going forward? Is there room to expand in the retail? Would love any color there. Second question, as you continue to grow your base of brand ambassadors, how do you plan to leverage that going forward? Is your strategy different as you look towards next year? Thank you.
Danny Yeung: Yeah. As mentioned now, we definitely plan to go into retail. Again, I think even from an investor perspective, this makes the business much more investable because we're not just a direct-to-consumer brand. People will be able to see us on the shelves. As mentioned, by 2027, we will have at least a hydration and Care Bears brand inside retail. So 100% on retail. In terms of our ambassador relationships, we look at a lot of our ambassador relationships on a case-by-case basis. As I mentioned earlier, every single one of these big ambassadors that comes in, they found us.
Normally, it's through a recommendation by their nutritionist, their doctor, or a friend, and they're taking the product, they're enjoying the product, they're using the product daily, and they come find us. I think these are the best type of partnerships where these ambassadors, they start off as users first, and they come in, and they want to partner with us. A lot of people ask me, Who are we going to sign up next? The reality is, I don't know who's going to reach out to us next, right? Once they reach out, we see if it's a fit for the brand.
Of course, it also has to fit in terms of the commercials, but because these individuals love IM8 so much, we're always able to get really good partnerships out of these.
Jonna Kim: Just one last question on, obviously, New Year is an important period for wellness products, and you're at a larger scale. Is there anything you are doing different in terms of your marketing strategy around the New Year time?
Danny Yeung: Yeah, I would say Q4 and Q1, right? I mean, Q4 and Q1 are going to be the biggest seasonality aspects in the business-wise. From Q1, again, new year, new you, so we will be launching hydration products in Q1, so I think that's going to be different, along with our current Essentials and Longevity products. One key thing I think you're going to see us continue to do is that we're continuing to do a lot of offline activation events, and you'll continue to see that, especially when we launch Hydration, because naturally, there's going to be many multiple flavors.
Our offline events, again, since 22 months ago, and that's one thing that really separates us from everyone else, is that people can see the product, they can talk to our scientific advisory board, they can talk to our ambassadors. I meet with them. So we've done now 200 plus events in the last 22 months, and I think that really puts a face to the product as well. I think with Hydration, we're going to do more of these type of activation events around the world.
Jonna Kim: No, thank you for the follow-up.
Operator: Thank you, Jonna. We'll go next to Alex Nowak of Lucid. Alex, you may proceed.
Alex Nowak: Okay, great. Good morning, everyone. Thanks for taking the time. Appreciate it. We talked a lot about the CAC throughout the call, but I just really want to keep it simple. You raised the second half loss due to the higher marketing spend, and you raised it because you clearly see the potential out there and you want to keep pushing hard. I get that. How come we didn't raise the revenue guidance, either for Q4 or for next year?
Danny Yeung: Yeah. Brian, you want to take that one?
Brian Rosin: Yeah. I mean, we have a fairly wide range there, just given that Q4, we filled the funnel up with a lot of customers that are aware of us from the Q3 push. We have a lot of customers in our mix now that hopefully will pull through as Black Friday comes around. Rather than us raise the revenue guidance, we decided to keep the fairly wide range there and hope that's sufficient. We also don't want to raise the mark too high to the point where we are unsure of how that will look. We feel confident with the revenue guide there just being a pretty wide range already.
Alex Nowak: Okay.
Danny Yeung: Yeah, and I would also add is that if you think about where we are today, again, the brand is 22 months old, right? In our second year, we've already achieved or will achieve $220 million plus in full year revenue, and next year we're targeting $400 million our third year. At least in the supplement category, no company has ever done that in such speed and such growth. So we feel we are at a very good point already, and we want to leave some upside up there, right? Again, I think Hydration we believe is a big category. Care Bears is a big category.
But we're so focused on growing the business today with new product development, growing existing business. We just felt at 400, it gives a lot of investors upside opportunities for us to capture on that.
Alex Nowak: Yep, absolutely. Even your shareholder letter mentioned, the plan behind 2027 sums to more than $400 million, so totally get that. I do want to go back on our prior point about partners, and you've added some really good partners. I'm super excited about the potential within the running community, just given the new Hydration launch. I know you can't, or the goal here is the partner uses it first and then comes to you, but you also get to focus a little bit more on certain channels. What else are you targeting in particular? Any particular sports that you would-
Danny Yeung: So we are looking to a few different individuals that can really help us push the envelope in China for when we launch in 2027. Besides that, again, every day it's been crazy busy, right? I think we're very excited and happy with our existing roster. So, I can't tell you that there's a specific new area that we're looking to from an ambassador partnership perspective. Like you said, Alex, I mean, the running club piece is a huge opportunity for Hydration, right? I think around the world you see running clubs being developed. Regardless if it's 50 people, 100 people. Diplo's running club is now 10,000 people, and he only started this like a year ago.
So that's a prime opportunity to be able to promote our Hydration product when it comes out in Q1.
Alex Nowak: Absolutely. All right. Well, thank you for the time. Appreciate it.
Operator: Thank you, Alex. Our next question comes from Ryan Meyers of Lake Street. Ryan?
Ryan Meyers: Hey, guys. Thanks for taking my questions. First one for me, just on the topic of the General Catalyst financing. With the financing now operating for a full quarter, how should we think about the relationship between new funding and repayments as the facility matures? Then maybe at what point do you think the business can begin generating positive operating cash flow independent of the General Catalyst funding?
Brian Rosin: Yeah, I mean, in the quarter, we repaid $7 million against draws of $31 million, then they owed us a few million at the end of the quarter as well. For quite some time, the amount that we're going to be drawing down for each individual month is going to exceed any of the repayment amounts in aggregate for a good amount of time. As you look out and you model the business into the future, it's more like, I would say 18 months into the arrangement is when I start to see the cash coming in more or less equivalent to the cash being repaid to them. So at that point, it becomes cash neutral.
However, cash neutral is a much different environment than us funding our own acquisition dollars at that point in time. Depending on how large the business is at that point and how much we're spending per month, that would all be our own cash out the door, whereas in this world, cash neutral in that environment is still really strong from a cash flow standpoint. You asked about when we would potentially be turning operating cash flow positive. It's similar to when we would potentially turn adjusted EBITDA positive, and we've not wanted to get too far ahead of ourselves in trying to guide when specifically that will happen.
Depending on how you model out the business, it becomes pretty difficult to outrun the math of how big the existing customer base is and how much contribution profit and dollars you're getting from your existing customer base. We have 160,000 subscribers right now. That number continues to go up. Your existing repeat revenue is going to continue to get so large that unless we continue to spend significant amounts, sequential growth period over period, it eventually becomes too hard to outrun the math of no matter how big we want to invest, when we want to hold ourselves to the 3-to-1 return on that, you'll reach a world where we'll cross the chasm to profitability.
That will, again, we don't want to put any specific timelines on it, but I would say it's not that far out into the future when that would happen, and it all comes down to how much are we able to keep spending at our 3-to-1 return at near our $300-ish CAC. We've been able to keep spending more and more at that number, and as time goes on, if we can continue to do that, then that'll just keep pushing out that chasm. But if we slow the growth or if we slow the spend, that number would come very fast.
We could become profitable next quarter if we slowed our spend, but that's not in the best interest of our shareholders long term.
Ryan Meyers: Okay, got it. Secondly, maybe for Danny Yeung, can you just sort of provide us with some commentary on what you think is allowing the IM8 brand specifically to drive the above average customer retention when it comes to supplements?
Danny Yeung: It is quite simple actually, right, on that part, because the product works. I think, again, starting from day one-wise, right, we had an amazing scientific advisory board, third-party testing, NSF certification. Then so when you drink it over a long period of time, you form a routine, it works, and you will continue with it. Then so I think that is the main reason why I think retention has been so powerful, right? I think we have also really focused not just on the functionality of it, but at the same time also on the taste. When we just launched, we had one flavor. We have now introduced two new flavors.
In Q1, we are going to introduce another flavor. So I think having these new updates on the formulation as well as on taste continually delights our existing customer base.
Ryan Meyers: Makes sense. Thanks for taking my questions.
Operator: Thank you, Ryan. We will go next to Tom Forte of Maxim. Tom?
Tom Forte: Great. Thanks, Shannon. Danny and Brian, thanks for taking my questions. I have two on artificial intelligence, and I am going to ask them at the same time. Can you give an update on how you are able to leverage artificial intelligence to scale the business without adding material headcount? Second, on agentic commerce, Meta has had tremendous engagement based on the number of downloads for Muse. How are you positioning yourselves to capitalize on that opportunity?
Danny Yeung: Great question, Tom. Good to connect. I think on the first part, in terms of how we're using AI, I think, again, if you look at least the direct-to-consumer space, the key thing actually for any company in this space is content. You need to have lots of content across many different channels. A lot of the aspects that we do use is basically utilizing AI to develop lots of content, regardless if it's static videos in combination with real shot videos and basically utilizing AI to cut them through to much more different content pieces.
So, for example, one of the clear examples, I think I shared this previously, is that if you look at our Meta public ads library, at any given time, we'll have three, four, 5,000 ads running live at any given time. What we'll do, we'll be able to utilize AI to identify the winners very fast. When we do identify winners, we'll then show these same ads on AppLovin, on X, on Snap, on TikTok, the same aspects. On a weekly basis, we're also testing a lot of new content, five, six, 700 pieces of content on a weekly basis, which, again, to be fair, if you don't know what you're doing, it's very, very difficult.
That's why there are very few brands that can scale at our levels. I think that gives you a clear example. That's why, again, even right now, if you look at our overall team base, we have approximately 70, 75 employees. If you think about our full-year revenue this year, which is going to be well more than $200 million, so it's roughly about $3 million revenue per employee per year. If we think about next year, looking at $400 million plus, we'll probably add 25, 30 people, so probably get to about 100 employees at $400 million. So that would be roughly about $4 million per employee per year. So we believe which are great metrics, right?
In terms of the agentic commerce piece, great question. Right now, we're actually testing in terms of even having ads within ChatGPT, which they've already opened up. I do believe it's still early days, but it's going to move very, very fast, right? I do believe within the next three to six months, or even a shorter pair of times, a lot of people are going to be using their AI to purchase things. Even for me, I'm using Muse, Instinct to buy things with that AI. So I couldn't imagine that's going to be a common place in the next three, six, 12 months.
Again, given the amount of work that we're already in this, we're doing with AI, we feel that we'll be able to lead the pack in that area.
Tom Forte: Thank you, Danny.
Operator: Our next question will come from Dylan Hines of B. Riley. Dylan, please go ahead.
Dylan Hines: Hey, great quarter. Thanks for taking the question. I just wanted to go back to the retail entry. Do you already have agreements with retail partners, and could you maybe provide any color on that, maybe which ones? Then what would the ramp look like? When do you expect, you think, you'll include the retail launch into guidance?
Danny Yeung: Yeah, so I think in terms of the retail aspect, transparently, we do not have any agreements. We've been, again, we've been hounded by all the major retail partners, I would say, for the last 12 months. This is something that I'm personally involved with in terms of working closely with that big box retailer. Again, we can't mention the name, but it's a big name in the US retail space, right? We expect that to go live by the end of 2027. I do believe right now it's still way too early to provide any type of guidance in terms of what that is.
Again, for us-wise, we're very optimistic about the opportunity given this big box retailer and our product scope and our product set that we have in place. Once we are in retail, I think very soon we will be able to give guidance in terms of how big the opportunity is.
Dylan Hines: Okay, got you. Going to the ambassador network, do you have any specific plans in terms of activations with the ambassadors? How do you convert the following visibility and subscriptions? Can you try to quantify any of the benefit from the ambassadors?
Danny Yeung: Yeah, 100%. I think every single one of our ambassadors have more than paid much more than what we have given them. It is actually quite easy for us to quantify. It is not just from the. To be fair, the offline activations is more brand activity events. For example, when we have a partnership with Giannis, Aryna Sabalenka, et cetera, one of the key things for us is content and digital profiling. We are able to utilize partnership and white listing ads. For example, Giannis, he has 20 million followers on Instagram. So we can market from Giannis's handle or Aryna's handle to their followers.
Speaker 4: From morning fields to star aisles, every fruit and vegetable is handpicked with care, sorted and checked at our collection centers, packed fresh and sent straight away, so farm freshness reaches star and your plate.
Danny Yeung: Ambassador, which is well-known, these will perform 20%-30% better than just a normal individual promoting that same product.
Dylan Hines: Gotcha.
Danny Yeung: It more than pays itself.
Dylan Hines: Gotcha. Okay, great. Thanks for taking the question.
Operator: Thank you, Dylan Hines. Our next question comes from George Kelly of Roth. George, please go ahead.
George Kelly: Everybody, thanks. Can you hear me?
Danny Yeung: Yes. Hey, George.
George Kelly: Hey, Danny Yeung. Thanks for taking the questions. A couple for you. I will start with, I think I heard in the prepared remarks that you are changing manufacturing partners. Did I hear that right? And can you give just the reasoning behind the change? Maybe it is related to the gummies or pricing. Not sure, so any detail there would be helpful.
Danny Yeung: Yeah, so for the manufacturing partners, actually, it is a new manufacturer partner we are bringing in place for our IM8 Hydration product, as well as adding additional capacity for our existing products. And of course, for the gummies, that is going to be a separate manufacturer as well.
George Kelly: I guess for the core product, though, are there changes coming?
Danny Yeung: For the core product, we're adding additional capacity, just in case. Because right now, to be fair, our scale is where we can't just be dependent on one manufacturer. So we're also adding another manufacturer just in case anything happens, right?
George Kelly: Okay. Understood. Second question from me, back to your guidance revision, the EBITDA change. Is it fair to say that I guess I'm just trying to dig into the trends you've seen with respect to CAC in October and November, and I'm wondering if there's been something that maybe wasn't fully appreciated in your prior guide. Maybe it's the election. Just trying to understand how CAC has changed versus your earlier expectations.
Danny Yeung: I mean, it hasn't changed much on a quarter-to-quarter basis, right? I think CAC was roughly about $285 in Q3. So again, we believe it'll fluctuate within 10%-15% of this range, roughly about $300, right? So we feel if we can maintain our spend, our CAC at current levels, we are in a good spot. The reason why we're in a good spot is because we know at this level of CAC, we'll be able to get payback within approximately six months, and we'll also be able to achieve that 3-to-1 ratio over a 36-month period of time.
George Kelly: Okay. Maybe if I could sneak in one more quick one. The updated gross margin target, the long-term target of 70%-75%, how much visibility do you have on that? Are these manufacturing changes and the new products and stuff a big part of it? It's a big jump, so I'm trying to understand your confidence.
Brian Rosin: Yeah, there's two parts. There's one that's on the manufacturing side, and there's the other piece that's on the fulfillment side. In both of those areas, I think we have identified some fairly low-hanging fruit of, as we get more economies of scale, we'll be able to get better pricing on some of those areas. I would say, we haven't figured out how to get to the upper range of that target. It's pretty clear to me how we're going to get towards the bottom part of that range with some work to be done for sure, but fairly straightforward to get there within four to six quarters, I would say.
Again, not specific guidance, but I would expect us to approach the lower range of that 70% number towards the end of next year at some point. Towards the 75%, as the business continues to grow and as we bring on additional capacity, you add some, again, more economies of scale, and on both parts of it, again, manufacturing and logistics. I think that we would be shooting for the upper range eventually, but the lower end is clearer in sight right now.
George Kelly: Okay. Thank you.
Operator: Thank you, George. Our next question comes from Kyle Bauser of Titan. Kyle, please go ahead.
Kyle Bauser: Great. Thanks for all the updates here. My first question is around price elasticity and any kind of competitive dynamics. You've obviously taken significant share from the top players, and we also saw that 87% of new IM8 customers had no observed purchase from AG1, Grüns, or Thorne before their first IM8 order. Just how have the pricing competitive dynamics been out there? Obviously, you've got a premium price on yours given the superior product, but should we expect continued pricing stability?
Danny Yeung: Yeah, I mean, we haven't seen much price issues for us. I mean, again, we haven't changed our pricing since we've I mean, actually, since we've launched, we've actually had a slight price increase, but we haven't seen any issues in terms of price elasticity or any type of demand, as you see evidenced by the continued growth on a quarterly basis.
Kyle Bauser: Got it. Maybe just around the clinical trials, can you talk a little bit more about how this might be unlocking new segments of the population? Obviously, consumers are getting much smarter, and awareness is certainly building. Do you anticipate results driving kind of new cohorts of consumers or
Speaker 4: I'm a brand manager, and my ClickUp looks like this. I'm a project manager. My ClickUp looks like this. I'm a product manager, and my ClickUp looks like this.
Danny Yeung: that consumer. We will be able to leverage that in terms of marketing. A lot of marketing and also, like you mentioned, clinicians will be able to prescribe it much more. Very, very positive and hopeful about these trials that are going to be releasing in the first half of 2027.
Kyle Bauser: Excellent. Well, thanks for all the updates.
Danny Yeung: Great.
Operator: Thank you, Kyle. Our last question comes from Alex Hantman of Sidoti. Alex, please go ahead.
Alex Hantman: Thank you, thanks for taking questions. I just wanted to start with repeat orders. They were looking great, 59% of customer billing this quarter. I am curious, as that share grows, how quickly does acquisition marketing come down towards your 35%-50% range, what does that mean for the timing of profitability?
Brian Rosin: Yeah, so the 59% is nice to see. However, if we can continue to invest at the three to one, we would rather keep spending more and more into new customers. So it is a conundrum in that when we spend more on customer acquisition, your percent of new revenue is higher, but that is a great sign for the future with the returns that we have. So, I would again say that profitability is not necessarily a goal. It is inevitable with the math that eventually it just becomes too hard to outrun it, as I mentioned a little bit ago.
So, it is hard to put a timeline on it because we have exceeded kind of where I would have expected us to have been able to spend up to at a CAC that is declining. If that continues, then of course we will continue to do that, at which point you push profitability out. If we start to slow to spend, it brings profitability forward in the nearer term. It is too tricky to try to say specifically when that will happen because we have been exceeding what I would have thought we could have been spending. Again, with new products and all that, we do not know how those are going to impact CAC.
We do not know how it is going to impact overall LTVs and LTRs. We need to get these products launched before we will be able to kind of model into the future more specifically around profitability target. I would expect that the marketing will continue to come down as a percentage of sales, which we saw it already from Q2 to Q3. I would expect that to trend mostly down. There might be some blips here and there, but mostly that will keep trending down to that range that we gave for longer term.
Alex Hantman: Okay, helpful context. Thank you. Speaking of new products, I know IM8 Hydration launches into about 160,000 active subscriptions. It is a big number. I am curious what attach rate would you consider a success in year one if you have a target, and also about how margins might compare to the core products?
Danny Yeung: I would say, IM8 Hydration and gummies were the two categories that when we did surveys with our existing customers, that they asked about, that they wanted us to provide. I would expect a minimum of 15%-20% against our existing subscriber base in terms of that will take up this. I think also, not just our existing customer base. The reality is, electrolyte hydration is a huge category. It potentially is even bigger than our existing supplements or daily nutrition category. I think we will also be able to get a lot of new people into the door that we can also cross and upsell them with our current Essentials and Longevity products.
Alex Hantman: Okay. Thank you.
Brian Rosin: Alex, from a margin standpoint, just to touch on the margin of those. The margin profile will be very similar to our current business margin, from a product cost standpoint, for sure. From a logistics standpoint, it depends on if we can trade people into a multi-month, or a bigger basket size and attach, whether it is our current products or an Essentials bundle. Or if you are getting a three-month supply of Hydration, for example, that will allow the margin to keep really in line with where we are today.
If we are seeing AOV start to decline, because people are taking more of the one-month supply of Hydration, which is a lower price point out the door than our current assortment, you might see a little bit of margin pressure just on the fulfillment side alone. It costs us more or less the same to ship a product to a consumer if they buy $50 worth as if they pay $100. You will see a bit of pressure potentially, depending on how AOV looks. We will be trying it on the DTC channel for sure to get people into a multipack, which would alleviate that pressure entirely. The retail piece is also the other unknown there.
The retail channel looks different from a margin profile, as you can imagine. Much lower cost on the fulfillment side, much lower cost on the actual ad dollars specific going into retail. As I model it out, I think the margin of the total new products will be very unchanged versus the current. There is going to be some pluses and minuses there, but overall, I would not expect it to be pressured much.
Alex Hantman: Very helpful. Thanks for the color. Last one from us. I know we have spoken about retail at length, but the 2027 bridge also includes about $19 million from marketplace and B2B. I know that is only about 5% of revenue, but I wanted to hear a little bit more about the B2B opportunity looks like and how fast perhaps that could grow from your perspective.
Danny Yeung: Yeah. On the marketplace aspect is like Amazon, B2B, we actually have a lot of other businesses reaching out to us as part of their wellness aspects. Again, it is still a small part of our overall business if you consider next year we are forecasting $400 million. I think the focus will still remain DTC and then retail, and then B2B and marketplace, these are more like ad hoc opportunities that we will pick up.
Alex Hantman: Great. Thank you very much.
Operator: Thank you, Alex. That concludes our question and answer session. I will now turn the call back over to Danny for brief closing remarks.
Danny Yeung: Great. Thank you so much, everyone, for tuning in today. Hopefully it was very insightful. As I mentioned, we have a very detailed shareholder letter and investor deck, that we just pushed online. Yeah, I mean, again, going back to summary-wise, this quarter is another record quarter. We are heading into 2027 with a lot of strength. The revenues are growing, the cash position is growing, our cohorts are growing, with new products. It is very clear to us, at least from a business perspective, that we are reaching stronger momentum on a quarterly and on a monthly basis. Yeah, so we cannot be more excited about where the business is headed.
So, thank you, everyone, for tuning in, and look forward to chatting with everyone in the next quarter.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.